Minoxidil topique 5 % face à Minoxidil topique 5 % une fois par jour + spironolactone orale 80 à 100 mg par jour

1 essai les comparent directement, sur les mêmes patients. Voir Minoxidil topique 5 % · Voir Minoxidil topique 5 % une fois par jour + spironolactone orale 80 à 100 mg par jour

En bref

Un essai de fiabilité moyenne, chez 120 femmes non ménopausées atteintes d'alopécie androgénétique, compare le minoxidil topique 5 % une fois par jour, seul ou avec de la spironolactone orale de 80 à 100 mg par jour (Liang 2022). L'ajout fait gagner plus de cheveux en 24 semaines : de 99,14 à 115,89 cheveux par cm², contre 101,37 à 111,32 sous minoxidil seul, un écart probablement réel ; 86,49 % des femmes sont améliorées sur photos, contre 55,27 %. En contrepartie, 15 femmes sur 37 ont des règles irrégulières sous spironolactone, contre aucune sous minoxidil seul. Les autres effets indésirables sont proches d'un groupe à l'autre.

Votre profil

Liang 2022

Essai randomisé, risque de biais modéré. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.

Critère	Minoxidil topique 5 %	Minoxidil topique 5 % une fois par jour + spironolactone orale 80 à 100 mg par jour	Écart
Densité capillaire totale12 semaines	101,37 → 102,47 cheveux par cm² 1 application par jour Voir la citation TABLE2\|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 \|Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 \|P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	99,14 → 111,89 cheveux par cm² Voir la citation TABLE2\|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 \|Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 \|P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Très probablement réel
Densité capillaire totale24 semaines	101,37 → 111,32 cheveux par cm² 1 application par jour Voir la citation TABLE2\|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 \|Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 \|P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	99,14 → 115,89 cheveux par cm² Voir la citation TABLE2\|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 \|Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 \|P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Probablement réel
Diamètre de la tige pilaire24 semaines	1 application par jour Voir la citation Hairshaftdiameter(mm) Baseline 44.07±4.79 43.10±4.29 42.85±7.07 Week12 51.38±9.82 53.24±6.58 51.03±9.05 Week24 58.43±10.04 58.09±9.32 58.24±11.44 \|Change 7.30±8.89 10.13±6.12 8.18±7.13 §Change 14.36±10.61 14.99±9.25 15.39±10.73 \|P-value <0.001 <0.001 <0.001 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 – – – – – – – – – – – 0.597 – – – – – – – – 0.114 0.632 0.051 0.249 0.785 0.672 0.863 0.905 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Voir la citation Hairshaftdiameter(mm) Baseline 44.07±4.79 43.10±4.29 42.85±7.07 Week12 51.38±9.82 53.24±6.58 51.03±9.05 Week24 58.43±10.04 58.09±9.32 58.24±11.44 \|Change 7.30±8.89 10.13±6.12 8.18±7.13 §Change 14.36±10.61 14.99±9.25 15.39±10.73 \|P-value <0.001 <0.001 <0.001 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 – – – – – – – – – – – 0.597 – – – – – – – – 0.114 0.632 0.051 0.249 0.785 0.672 0.863 0.905 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Peut être dû au hasard
Patients améliorés (panel photo en aveugle)24 semaines	55,27 % 1 application par jour Voir la citation Assessed by investigators according to global photographs, 55.27% of patients in the MX group, 86.49% of patients in the MX + SPT group, and 95.00% of patients in the MX + MN group showed improvement at week 24 (Figure4). Among the Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	86,49 % Voir la citation Assessed by investigators according to global photographs, 55.27% of patients in the MX group, 86.49% of patients in the MX + SPT group, and 95.00% of patients in the MX + MN group showed improvement at week 24 (Figure4). Among the Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Chute initiale sous minoxidil24 semaines	4 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	4 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Hyperkaliémie24 semaines	0 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	1 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Hypotension orthostatique24 semaines	1 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	0 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Incidence d'une pilosité accrue24 semaines	4 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	5 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Incidence de céphalées24 semaines	1 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	1 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Infection24 semaines	0 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	0 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Palpitations24 semaines	1 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	3 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Pellicules24 semaines	7 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	6 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Prurit24 semaines	8 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	8 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Troubles des règles24 semaines	0 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	15 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Urticaire24 semaines	1 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	1 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé
Œdèmes des membres24 semaines	0 sur 38 1 application par jour Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	1 sur 37 Voir la citation TABLE5\|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY.	Non testé